Danaher Expands Board with Comas and Hershberg Amid Strategic Refresh

  • Danaher added Daniel Comas and Robert Hershberg to its board on October 9, 2026, expanding it from 11 to 13 directors.
  • Alan Spoon will retire from the board at the 2027 annual meeting.
  • Comas brings deep Danaher experience, including CFO and executive roles, while Hershberg adds biopharmaceutical and scientific expertise.
  • Hershberg also joins the Science and Technology Committee.
  • Danaher co-founders waived 500,000 restricted stock units each.

Danaher's board refresh signals a focus on deepening strategic and scientific expertise amid a competitive life sciences landscape. The additions come as the company navigates post-pandemic demand shifts and the integration of high-profile acquisitions. With $30B+ in annual revenue, governance moves at this scale often precede major strategic pivots or portfolio realignments.

Governance Dynamics
How the addition of Comas and Hershberg will influence Danaher's strategic direction and capital allocation decisions.
Biotech Integration
Whether Hershberg's biopharmaceutical expertise can accelerate Danaher's innovation pipeline in life sciences.
Execution Risk
The pace at which Danaher can integrate recent acquisitions, particularly Masimo, while maintaining operational excellence.